News & Updates
Showing Oncology articles
Showing
Tremelimumab plus durvalumab improves survival in Asians with unresectable HCC
A single tremelimumab regular interval durvalumab (STRIDE) provides survival benefits to Asian patients with unresectable hepatocellular carcinoma (HCC), as shown by the results of the HIMALAYA study.
Recurrence scores from 21-gene assay help inform benefits of adjuvant anthracyclines in EBC
The recurrence score derived from a 21-gene expression assay may indicate which patients with early-stage HR+ breast cancer can maintain freedom from distant recurrence for longer with the inclusion of an anthracycline in adjuvant chemotherapy, suggests a post hoc analysis of the TAILORx trial presented at SABCS 2024
Toripalimab plus chemo a good 1st-line CHOICE for advanced NSCLC
The prespecified final analysis of the phase III CHOICE-01 trial of toripalimab in combination with chemotherapy shows significant improvement in overall survival (OS) in treatment-naïve patients with advanced non-small-cell lung cancer (NSCLC) without EGFR/ALK driver mutations.
Could intermediate use of H1-antihistamines alongside ICIs extend OS in lung cancer?
A retrospective territory-wide cohort study by the Chinese University of Hong Kong (CUHK) reports an association between intermediate use of H1-antihistamines and longer overall survival (OS) in patients with lung cancer treated with immune checkpoint inhibitors (ICIs).
